We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve
Read MoreHide Full Article
Tandem Diabetes Care, Inc. (TNDM - Free Report) reported loss per share of 9 cents in third-quarter 2019, significantly narrower than the year-ago loss of 62 cents. The Zacks Consensus Estimate was pegged at loss of 20 cents per share.
Revenues in Detail
Revenues in the quarter were $94.7 million, surpassing the Zacks Consensus Estimate by 7%. The top line skyrocketed 104.6% from the year-earlier period’s $46.3 million on strong domestic demand for the t:slim X2 insulin pump.
Per management, the rollout of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales along with its international launch strengthened the company’s core business and considerably drove top-line growth in the third quarter.
In the quarter, Tandem Diabetes’ global pump shipments soared 111.5% year over year to 17,839 units. Of these, 4,025 pumps were shipped to international markets. Accordingly, Tandem Diabetes registered international sales of $15.8 million in the period.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
Domestic pump shipments surged 87.2% year over year to 13,814 units. Domestic sales were $78.8 million, up 80.3% year over year.
Interestingly, the company began shipping pumps to select geographies for commencing international operations last August.
Margins
Gross profit in the reported quarter was $50.7 million, marking significant 132.5% growth from the prior-year period. Gross margin was 53.5%, expanding 643 basis points (bps).
Total operating expenses were $56.7 million, up 51.1% year over year. Operating loss in the quarter under review was $6 million compared with $15.7 million a year ago.
Financial Position
Tandem Diabetes exited the third quarter of 2019 with cash and cash equivalents of $156.9 million compared with $131.4 million in the last reported quarter.
Guidance
Banking on a promising third-quarter show, Tandem Diabetes has increased the lower end of its sales estimates to $358-$365million (from $350-$365 million mentioned earlier). The updated range indicates annual sales growth of around 95-99%. The Zacks Consensus Estimate for the top line is pegged at $359.3 million, which lies within the company’s projected range.
Our Take
Tandem Diabetes delivered better-than-expected results in the third quarter. Strength in the t:slim X2 Insulin pump’s domestic sales and the company’s expansion in international markets as well as a robust product pipeline drove the top line significantly in the quarter. We are impressed with the surge in global pump shipments. The company’s updated sales forecast for 2019 also looks promising.
However, its heavy dependence on insulin pump sales and recurring operating loss are concerning.
Zacks Rank & Stocks to Consider
Currently, Tandem Diabetes carries a Zacks Rank #3 (Hold).
Some better-ranked medical device companies, which posted solid results this earnings season, are ResMed Inc (RMD - Free Report) , NuVasive, Inc and Thermo Fisher Scientific Inc (TMO - Free Report) .
ResMed, with a Zacks Rank #2 (Buy), reported first-quarter fiscal 2020 adjusted EPS of 93 cents, surpassing the Zacks Consensus Estimate by 6.9%. Its revenues of $681.1 million outpaced the consensus mark by 3.7%.
NuVasive’s third-quarter 2019 adjusted EPS of 59 cents surpassed the Zacks Consensus Estimate by 9.3%. Its revenues totaled $290.8 million, which surpassed the consensus estimate by 2.4%. The stock currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher, with a Zacks Rank #2, delivered third-quarter 2019 adjusted EPS of $2.94, beating the Zacks Consensus Estimate by 2.1%. Its revenues of $6.27 billion beat the Zacks Consensus Estimate by 1.3%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve
Tandem Diabetes Care, Inc. (TNDM - Free Report) reported loss per share of 9 cents in third-quarter 2019, significantly narrower than the year-ago loss of 62 cents. The Zacks Consensus Estimate was pegged at loss of 20 cents per share.
Revenues in Detail
Revenues in the quarter were $94.7 million, surpassing the Zacks Consensus Estimate by 7%. The top line skyrocketed 104.6% from the year-earlier period’s $46.3 million on strong domestic demand for the t:slim X2 insulin pump.
Per management, the rollout of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales along with its international launch strengthened the company’s core business and considerably drove top-line growth in the third quarter.
In the quarter, Tandem Diabetes’ global pump shipments soared 111.5% year over year to 17,839 units. Of these, 4,025 pumps were shipped to international markets. Accordingly, Tandem Diabetes registered international sales of $15.8 million in the period.
Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise
Tandem Diabetes Care, Inc. price-consensus-eps-surprise-chart | Tandem Diabetes Care, Inc. Quote
Domestic pump shipments surged 87.2% year over year to 13,814 units. Domestic sales were $78.8 million, up 80.3% year over year.
Interestingly, the company began shipping pumps to select geographies for commencing international operations last August.
Margins
Gross profit in the reported quarter was $50.7 million, marking significant 132.5% growth from the prior-year period. Gross margin was 53.5%, expanding 643 basis points (bps).
Total operating expenses were $56.7 million, up 51.1% year over year. Operating loss in the quarter under review was $6 million compared with $15.7 million a year ago.
Financial Position
Tandem Diabetes exited the third quarter of 2019 with cash and cash equivalents of $156.9 million compared with $131.4 million in the last reported quarter.
Guidance
Banking on a promising third-quarter show, Tandem Diabetes has increased the lower end of its sales estimates to $358-$365million (from $350-$365 million mentioned earlier). The updated range indicates annual sales growth of around 95-99%. The Zacks Consensus Estimate for the top line is pegged at $359.3 million, which lies within the company’s projected range.
Our Take
Tandem Diabetes delivered better-than-expected results in the third quarter. Strength in the t:slim X2 Insulin pump’s domestic sales and the company’s expansion in international markets as well as a robust product pipeline drove the top line significantly in the quarter. We are impressed with the surge in global pump shipments. The company’s updated sales forecast for 2019 also looks promising.
However, its heavy dependence on insulin pump sales and recurring operating loss are concerning.
Zacks Rank & Stocks to Consider
Currently, Tandem Diabetes carries a Zacks Rank #3 (Hold).
Some better-ranked medical device companies, which posted solid results this earnings season, are ResMed Inc (RMD - Free Report) , NuVasive, Inc and Thermo Fisher Scientific Inc (TMO - Free Report) .
ResMed, with a Zacks Rank #2 (Buy), reported first-quarter fiscal 2020 adjusted EPS of 93 cents, surpassing the Zacks Consensus Estimate by 6.9%. Its revenues of $681.1 million outpaced the consensus mark by 3.7%.
NuVasive’s third-quarter 2019 adjusted EPS of 59 cents surpassed the Zacks Consensus Estimate by 9.3%. Its revenues totaled $290.8 million, which surpassed the consensus estimate by 2.4%. The stock currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher, with a Zacks Rank #2, delivered third-quarter 2019 adjusted EPS of $2.94, beating the Zacks Consensus Estimate by 2.1%. Its revenues of $6.27 billion beat the Zacks Consensus Estimate by 1.3%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>